Houlihan Lokey Advises Gridiron Capital on its Partnership with van den Boom & Associates

Houlihan Lokey is pleased to announce that Gridiron Capital (Gridiron) has partnered with van den Boom & Associates (vdB&A or the Company). The transaction closed in July 2026.

vdB&A provides life sciences companies with an embedded, full-suite outsourced back-office solution that spans finance and accounting, human resources, contract management, compliance, and a newly launched information technology (IT) managed services offering. The Company serves 160+ active clients with a team of 150+ professionals, supporting companies at every stage of growth, from newly formed startups to public companies. Founded by Esther van den Boom in 2014, vdB&A is headquartered in San Diego, California, with additional offices in Boston, Jacksonville, Minneapolis, and the Philippines.

The partnership with vdB&A underscores Gridiron’s conviction in its Outsourced Pharma Services Thematic Area of Expertise™ and builds on the firm’s experience partnering with healthcare and pharma-adjacent services businesses, most recently being Gridiron’s investment in Health Monitor Network. Gridiron will support vdB&A’s continued growth by leveraging its Centers of Excellence to help grow the core offerings and expand into adjacent services, and invest in tech-enablement, data analytics, and organizational development as the Company scales.

Gridiron Capital is an investment firm focused on partnering with founders, entrepreneurs, and management teams, and creating value by building middle-market companies into industry-leaders in business services, consumer products & services, and industrial growth segments in the United States and Canada. The firm helps transform growing companies by winning together through hard work, partnerships grounded in shared values, and a unique culture that comes from hands-on experience building and running businesses.

Houlihan Lokey served as a financial advisor to Gridiron Capital. This deal highlights Houlihan Lokey’s leading experience in the pharma services space and represents the firm’s thirty-eighth transaction in this sector since 2019.

RELATED: Pharma Services, Mergers and Acquisitions